Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Provincial Landscape
Snapshot: 2026-10-21
Taiwan Multiple Myeloma Active Trials & Centers
As of 2026-10-21, there are 6 active clinical trials for multiple myeloma hosted across 13 tertiary medical centers in Taiwan (including National Taiwan University Hospital, Taipei Veterans General Hospital, China Medical University Hospital, etc.).
Active Trials
6
Hospitals
13
Therapies
Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents
Participating Medical Centers (13)
National Taiwan University HospitalTaipei Veterans General HospitalChina Medical University HospitalNational Taiwan University HospitalChina Medical University HospitalNational Taiwan University HospitalHualien Tzu Chi Medical CenterKaohsiung Medical University Chung-Ho Memorial HospitalTaichung Veterans General HospitalChang Gung Medical Foundation - Kaohsiung BranchE-DA Cancer HospitalFar Eastern Memorial HospitalNational Cheng Kung University Hospital
Active Studies in Taiwan (6)
Population synthesized by CMDNShowing 33 published English records of 6 registry trials.
Phase IIICTR20262221
RecruitingA Phase III, Randomized Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy (Including an Anti-CD38 Antibody and Lenalidomide)
Population: Relapsed/refractory
Target: Trispecific antibody targeting BCMA, GPRC5D, and CD3
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, CAMS)、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center、Shanghai Fourth People's Hospital 等 222 家中心
Clinical StudyCTR20250938
RecruitingELRANATAMAB Post-Trial Access: An Open-Label, Single-Arm Study for Multiple Myeloma Study Participants Continuing in Pfizer-Sponsored ELRANATAMAB Clinical Studies
Population: Multiple myeloma
Target: bispecific antibody
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Peking University Third Hospital、Shandong Provincial Hospital、Nanfang Hospital, Southern Medical University 等 7 家中心
Phase IIICTR20253414
RecruitingA Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of SG301 Injection Combined with Pomalidomide and Dexamethasone Versus Placebo Combined with Pomalidomide and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Population: Relapsed/refractory
Target: Novel monoclonal antibody targeting CD38
Study Sites: The First Affiliated Hospital of Soochow University、Beijing Chaoyang Hospital, Capital Medical University、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Tianjin Medical University Cancer Institute & Hospital 等 78 家中心
Phase I/IIaCTR20223160
RecruitingA Multicenter, Non-Randomized, Open-Label Phase I/IIa Clinical Study Evaluating the Safety, Tolerability, and Efficacy of ICP-490 Monotherapy and in Combination with Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Oral small-molecule "molecular glue" degrader
Study Sites: Peking University People's Hospital、Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine、Shengjing Hospital of China Medical University、Henan Cancer Hospital 等 6 家中心
Phase IIICTR20233883
RecruitingAn Open-Label, Two-Arm, Multicenter, Randomized, Phase III Study Evaluating the Efficacy and Safety of ELRANATAMAB (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone in Study Participants with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible or Deferred Transplant
Population: Newly diagnosed/Relapsed/refractory
Target: BCMA × CD3 bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center 等 17 家中心
Phase I/IIaCTR20233309
RecruitingA Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characteristics of KQ-2003 CAR-T Cells in Patients with Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Autologous BCMA/CD19 dual-targeting CAR-T
Study Sites: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital of Nanchang University、Peking University First Hospital、Henan Cancer Hospital 等 10 家中心
Phase IICTR20230238
RecruitingA Phase II, Open-label, Single-arm, Multicenter Clinical Study Evaluating the Efficacy and Safety of BCMA-targeted Chimeric Antigen Receptor T-cell Injection (CART-BCMA) in Patients with Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: BCMA-targeted CAR-T cell therapy
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Beijing Jishuitan Hospital、Affiliated Hospital of Hebei University 等 25 家中心
Phase IIICTR20223338
RecruitingA Phase 3, 2-Stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Population: Relapsed/refractory
Target: Next-generation "molecular glue" degrader (CELMoD)
Study Sites: Beijing Chao-Yang Hospital, Capital Medical University (East Campus)、Xi'an International Medical Center Co., Ltd.、Peking University First Hospital、Beijing Chao-Yang Hospital, Capital Medical University (West Campus) 等 32 家中心
Phase ICTR20241210
RecruitingA Multicenter, Open-Label Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HMPL-506 in Hematologic Malignancies
Population: Relapsed/refractory
Target: Small molecule targeted drug
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Nanfang Hospital of Southern Medical University、Qilu Hospital of Shandong University、Shengjing Hospital of China Medical University 等 13 家中心
Phase IIICTR20230801
RecruitingAn Open-Label, Single-Arm, Multicenter Clinical Trial Evaluating the Efficacy and Safety of Pomalidomide Capsules Combined with Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Pomalidomide
Study Sites: Beijing Chaoyang Hospital, Capital Medical University、Puyang Oilfield General Hospital、Shangqiu First People's Hospital、Puyang Anyang District Hospital 等 28 家中心
Phase IIICTR20241434
RecruitingA Phase III, Randomized Study Comparing Teclistamab in Combination With Subcutaneous (SC) Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With SC Daratumumab and Lenalidomide (Tal-DR) Versus SC Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Not Eligible or Not Planned for Autologous Stem Cell Transplantation as Initial Therapy
Population: Newly diagnosed
Target: BCMA × CD3 bispecific antibody (MajestTEC-7 study)
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Renji Hospital, Shanghai Jiao Tong University School of Medicine、Henan Cancer Hospital、Sun Yat-sen University Cancer Center 等 32 家中心
Phase ICTR20221007
RecruitingA Phase I Clinical Trial of HRS-3738 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma
Population: Relapsed/refractory
Target: Small molecule oral targeted drug / Next-generation EED (embryonic ectoderm development protein) inhibitor
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University、Henan Cancer Hospital、Shanxi Province Cancer Hospital 等 37 家中心
Phase ICTR20230879
RecruitingA Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KYS202002A Monoclonal Antibody Injection in Patients with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Recombinant humanized anti-CD38 monoclonal antibody
Study Sites: Beijing Chaoyang Hospital, Capital Medical University、Shengjing Hospital of China Medical University、Zhongshan Hospital, Fudan University、Sun Yat-sen University Cancer Center 等 7 家中心
Phase IIICTR20253381
RecruitingA Randomized, Controlled, Multicenter, Open-Label Phase III Study Evaluating the Efficacy and Safety of QLS32015 for Injection Monotherapy Versus Investigator's Choice of Regimen in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Population: Relapsed/refractory
Target: GPRC5D/CD3 bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital、First Affiliated Hospital of Kunming Medical University、Yunnan Cancer Hospital 等 82 家中心
Phase ICTR20262569
RecruitingA Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of 6MW5311 in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, and Multiple Myeloma
Population: Relapsed/refractory
Target: LILRB4 and CD3 bispecific antibody
Study Sites: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine、Henan Cancer Hospital、The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University 等 8 家中心
Phase IIICTR20232917
RecruitingA Two-Stage, Randomized, Multicenter, Controlled, Open-Label, Phase III Study Comparing Iberdomide Maintenance Therapy with Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
Population: Newly diagnosed/Maintenance
Target: Oral small-molecule "molecular glue" degrader (next-generation Cereblon E3 ligase modulator [CELMoD])
Study Sites: Peking University People's Hospital、Tongji Medical College of Huazhong University of Science and Technology、Qilu Hospital of Shandong University、Jiangsu Province Hospital 等 37 家中心
Phase ICTR20233717
RecruitingA Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of GLB-002 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Population: Relapsed/refractory
Target: Molecular glue degrader
Study Sites: Peking University Cancer Hospital、Henan Cancer Hospital、Jiangxi Cancer Hospital、Tianjin Medical University Cancer Institute and Hospital 等 13 家中心
Phase ICTR20242335
RecruitingAn Open-Label, Multicenter Phase I Clinical Study of SHR-9539 Injection Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients with Multiple Myeloma
Population: Multiple myeloma
Target: BCMA × CD3-targeting bispecific antibody
Study Sites: West China Hospital of Sichuan University、The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University、Jiangxi Provincial People's Hospital 等 28 家中心
Phase I/IICTR20241689
RecruitingA Phase I/II, Open-Label, Multicenter, Modular Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 Monotherapy or in Combination with Anticancer Agents in Participants with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Antibody-drug conjugate (ADC)
Study Sites: Peking University People's Hospital、Shengjing Hospital of China Medical University (The Second Affiliated Hospital of China Medical University)、Sun Yat-sen University Cancer Center、The Third Xiangya Hospital of Central South University
Phase IICTR20250778
RecruitingAn Open-Label, Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of F182112 in Combination with Different Dosing Regimens for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Recombinant Humanized Anti-BCMA/CD3 Bispecific Antibody for Injection
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital of Bengbu Medical University、The First Affiliated Hospital of Chongqing Medical University、Gansu Provincial Hospital 等 44 家中心
Phase IICTR20231956
RecruitingAn International, Multicenter, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Continue to Benefit From an Isatuximab-Based Treatment Following Completion of a Phase I, II, or III Parent Study
Population: Multiple myeloma
Target: Anti-CD38 monoclonal antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Royal North Shore Hospital、Instituto COI de Educacao e Pesquisa、James Lind Centro de investigacion del cancer 等 21 家中心
Phase IICTR20252454
RecruitingA Multicenter, Open-label Phase II Study Evaluating QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Population: Multiple myeloma
Target: T-cell redirecting bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital、Nanyang Central Hospital、The First Affiliated Hospital of Zhengzhou University 等 50 家中心
Phase IIICTR20260453
RecruitingA Multicenter, Open-label, Randomized Phase III Clinical Trial Comparing the Efficacy and Safety of GR1803 Injection Versus Daratumumab + Pomalidomide + Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received 1-3 Prior Lines of Therapy (Including Lenalidomide and a Proteasome Inhibitor)
Population: Relapsed/refractory
Target: BCMA-targeting bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、Henan Cancer Hospital、Shengjing Hospital of China Medical University 等 67 家中心
Phase ICTR20260785
RecruitingA Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetic Profile, Safety, Tolerability, and Immunogenicity of HLX15-SC Versus DARZALEX FASPRO; Combined with Lenalidomide-Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation
Population: Newly diagnosed
Target: Recombinant fully human anti-CD38 monoclonal antibody
Study Sites: Zhongshan Hospital, Fudan University、Peking University Third Hospital、Guangzhou First People's Hospital、The Third Hospital of Hebei Medical University 等 66 家中心
Phase 3CTR20200081
RecruitingA Phase 3, Multicenter, Randomized, Open-Label Study Comparing Venetoclax Plus Dexamethasone Versus Pomalidomide Plus Dexamethasone in Participants with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Oral small molecule targeted drug (BCL-2 inhibitor)
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Guangdong Provincial People's Hospital、The First Affiliated Hospital of Soochow University、Peking Union Medical College Hospital 等 19 家中心
Phase I/IICTR20232974
RecruitingA Multicenter, Open-label, Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-034 in Patients with Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: GPRC5D × CD3 bispecific antibody
Study Sites: Peking University People's Hospital、The First Affiliated Hospital of Henan University of Science and Technology、Qingdao Municipal Hospital、Shenzhen Second People's Hospital 等 21 家中心
Phase IICTR20261752
RecruitingA Multicenter, Open-Label Phase II Study Evaluating QLS4131 for Injection in Combination Therapy for the Treatment of Malignant Plasma Cell Neoplasms
Population: Multiple myeloma
Target: Trispecific antibody targeting BCMA, CD3, and GPRC5D
Study Sites: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital、Heze Municipal Hospital 等 39 家中心
Phase IIICTR20262035
RecruitingA Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Study of IBI3003 Versus Investigator's Choice of Regimen (DPd or PVd) on the Efficacy and Safety in Participants with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: GPRC5D/BCMA/CD3 trispecific antibody
Study Sites: Zhongshan Hospital, Fudan University、The First Affiliated Hospital, Zhejiang University School of Medicine、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The Affiliated Hospital of Xuzhou Medical University 等 45 家中心
Phase ICTR20242943
RecruitingA Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HP-001 Capsules in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
Population: Relapsed/refractory
Target: Small-molecule chemical drug
Study Sites: West China Hospital, Sichuan University、Henan Cancer Hospital、The First Affiliated Hospital of Nanchang University、Anhui Provincial Cancer Hospital 等 26 家中心
Phase I/IICTR20233843
RecruitingA Multicenter, Open-label, Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CM313(SC) Injection as Monotherapy and in Combination with Other Antineoplastic Therapies in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Population: Relapsed/refractory
Target: Recombinant humanized anti-CD38 monoclonal antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University、Hunan Cancer Hospital 等 16 家中心
Phase IIICTR20242452
RecruitingA Phase III, Multicenter, Randomized, Open-Label Study Comparing Etentamig with Available Standard of Care Therapies in Participants with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Population: Relapsed/refractory
Target: BCMA × CD3 bispecific T-cell engager (BiTE)
Study Sites: The First Affiliated Hospital of Nanchang University、Shanghai Tongji Hospital、Sun Yat-sen University Cancer Center、Henan Cancer Hospital 等 19 家中心
Phase ICTR20232373
RecruitingA Phase I Clinical Trial of QLS32015 for Injection Evaluating Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy in Patients with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: GPRC5D × CD3-targeting bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital、Shandong Cancer Hospital affiliated to Shandong First Medical University、The First Affiliated Hospital of Nanchang University 等 11 家中心
Phase IIICTR20221556
RecruitingA Phase III, Multicenter, Open-label, Randomized Study Evaluating the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 8)
Population: Relapsed/refractory
Target: Antibody-drug conjugate (ADC) targeting BCMA
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Sun Yat-sen University Cancer Center、Shengjing Hospital of China Medical University、Peking University Third Hospital 等 11 家中心